FDA grants fast track designation for Aldeyra’s eye disease drug

LEXINGTON, Mass. - Aldeyra Therapeutics, Inc. (Nasdaq:ALDX), a biotechnology company with a market capitalization of $324 million, announced Tuesday that the U.S. Food and Drug Administration has granted fast track designation for its drug ADX-2191 for the treatment of retinitis pigmentosa, a rare genetic eye disease affecting over one million people worldwide. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet.

The designation, combined with previously received Orphan Drug Designation, creates a regulatory pathway that could expedite the development and review process for ADX-2191, an intravitreal methotrexate injection. Fast track status enables more frequent FDA interactions and may allow for rolling review, priority review, or accelerated approval if relevant criteria are met. The company’s stock has shown resilience, posting a 9% gain year-to-date, while maintaining a healthy current ratio of 2.86x, indicating strong short-term liquidity.

Retinitis pigmentosa encompasses a group of rare genetic eye diseases characterized by retinal cell death and progressive vision loss. Currently, there are no approved treatments for most forms of the condition.

The potential effectiveness of ADX-2191 is supported by Phase 2 clinical trial results announced in 2023, which demonstrated improvements in retinal sensitivity following treatment. Aldeyra plans to initiate a Phase 2/3 clinical trial of the drug in 2025.

"Fast Track Designation in conjunction with the previously announced Orphan Drug Designation underscores the potential for ADX-2191 to address an unmet need in the field of ophthalmology," said Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, according to the company’s press release. Analysts share this optimism, with InvestingPro showing price targets ranging from $6 to $13 per share, suggesting significant potential upside. Get access to 6 more exclusive InvestingPro Tips and comprehensive financial analysis with an InvestingPro subscription.

ADX-2191 is a sterile, non-compounded intravitreal formulation of methotrexate designed to be vitreous-compatible and optimized for administration in the eye. The drug has also received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma and EMA Orphan Designation for the treatment of inherited retinal dystrophies and primary large B-Cell lymphomas of immune privileged sites.

In other recent news, Aldeyra Therapeutics announced significant developments concerning its drug pipeline. The U.S. Food and Drug Administration (FDA) accepted Aldeyra’s resubmitted New Drug Application for reproxalap, a treatment for dry eye disease, setting a target action date for December 16, 2025. This acceptance follows a clinical trial that successfully met its primary endpoint. Additionally, the European Medicines Agency granted Orphan Designation to Aldeyra’s ADX-2191 for treating inherited retinal dystrophies, including retinitis pigmentosa. In another development, the FDA provided a Special Protocol Assessment for Aldeyra’s investigational drug ADX-2191 for primary vitreoretinal lymphoma, with a clinical trial set to commence in the latter half of 2025. On the financial front, Jones Trading raised its price target for Aldeyra to $9 from $6, maintaining a Buy rating, following the FDA’s acceptance of the reproxalap application. These developments highlight Aldeyra’s ongoing efforts in advancing its treatments through regulatory processes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.